244 related articles for article (PubMed ID: 37901249)
1. Current biologics in treatment of pemphigus foliaceus: a systematic review.
Carver CA; Kalesinskas M; Ahmed AR
Front Immunol; 2023; 14():1267668. PubMed ID: 37901249
[TBL] [Abstract][Full Text] [Related]
2. Treatment of Pediatric Pemphigus Foliaceus.
Carver C; Kalesinskas M; Dheden N; Ahmed AR
Cureus; 2023 Sep; 15(9):e45373. PubMed ID: 37779684
[TBL] [Abstract][Full Text] [Related]
3. Retrospective analysis of a single-center clinical experience toward development of curative treatment of 123 pemphigus patients with a long-term follow-up: efficacy and safety of the multidrug protocol combining intravenous immunoglobulin with the cytotoxic immunosuppressor and mitochondrion-protecting drugs.
Grando SA
Int J Dermatol; 2019 Jan; 58(1):114-125. PubMed ID: 30047585
[TBL] [Abstract][Full Text] [Related]
4. First line treatment of pemphigus vulgaris with a novel protocol in patients with contraindications to systemic corticosteroids and immunosuppressive agents: Preliminary retrospective study with a seven year follow-up.
Ahmed AR; Nguyen T; Kaveri S; Spigelman ZS
Int Immunopharmacol; 2016 May; 34():25-31. PubMed ID: 26919279
[TBL] [Abstract][Full Text] [Related]
5. Intravenous immunoglobulin therapy for patients with pemphigus foliaceus unresponsive to conventional therapy.
Ahmed AR; Sami N
J Am Acad Dermatol; 2002 Jan; 46(1):42-9. PubMed ID: 11756944
[TBL] [Abstract][Full Text] [Related]
6. Four mild but refractory cases of pemphigus foliaceus successfully treated with intravenous immunoglobulin.
Kawakami T; Koga H; Saruta H; Ueda A; Inoue Y; Soma Y; Ishii N; Hashimoto T
J Dermatol; 2013 Nov; 40(11):869-73. PubMed ID: 24127870
[TBL] [Abstract][Full Text] [Related]
7. Rituximab and intravenous immunoglobulin as alternatives to long-term systemic corticosteroids in the treatment of pemphigus: a single center case series of 63 patients.
Brown AE; Motaparthi K; Hsu S
Dermatol Online J; 2018 Jan; 23(12):. PubMed ID: 29447653
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic features of pemphigus vulgaris in patients with pemphigus foliaceus: detection of both autoantibodies, long-term follow-up and treatment responses.
Sami N; Bhol KC; Ahmed AR
Clin Exp Immunol; 2001 Sep; 125(3):492-8. PubMed ID: 11531959
[TBL] [Abstract][Full Text] [Related]
9. IgM Deficiency in Autoimmune Blistering Mucocutaneous Diseases Following Various Treatments: Long Term Follow-Up and Relevant Observations.
Ahmed AR; Aksoy M
Front Immunol; 2021; 12():727520. PubMed ID: 34646266
[TBL] [Abstract][Full Text] [Related]
10. [Adjuvant therapy of pemphigus vulgaris and pemphigus foliaceus with intravenous immunoglobulins].
Enk AH; Knop J
Hautarzt; 1998 Oct; 49(10):774-6. PubMed ID: 9857253
[TBL] [Abstract][Full Text] [Related]
11. Long-term prognosis of pemphigus in Korea: retrospective analysis of 199 patients.
Kim MR; Kim HC; Kim SC
Dermatology; 2011; 223(2):182-8. PubMed ID: 22025028
[TBL] [Abstract][Full Text] [Related]
12. Steroid sparing effect of intravenous immunoglobulin therapy in patients with pemphigus foliaceus.
Sami N; Qureshi A; Ahmed AR
Eur J Dermatol; 2002; 12(2):174-8. PubMed ID: 11872417
[TBL] [Abstract][Full Text] [Related]
13. Intravenous immunoglobulin therapy in the treatment of patients with pemphigus vulgaris unresponsive to conventional immunosuppressive treatment.
Ahmed AR
J Am Acad Dermatol; 2001 Nov; 45(5):679-90. PubMed ID: 11606916
[TBL] [Abstract][Full Text] [Related]
14. A 6-year treatment experience for pemphigus: retrospective study of 69 Chinese patients.
Bai YX; Zhang LM; Xiao T; Chen HD
Dermatol Ther; 2016; 29(2):84-7. PubMed ID: 27060935
[TBL] [Abstract][Full Text] [Related]
15. Comparison of rituximab and intravenous immunoglobulin in the treatment of autoimmune bullous diseases: Real-life data from a single centre.
Huseynova Terzi L; Akdogan N; Dogan Gunaydin S; Atakan N
Int J Clin Pract; 2021 Dec; 75(12):e14955. PubMed ID: 34610193
[TBL] [Abstract][Full Text] [Related]
16. Rituximab and low dose oral immune modulating treatment to maintain a sustained response in severe pemphigus patients.
Keeley JM; Bevans SL; Jaleel T; Sami N
J Dermatolog Treat; 2019 Jun; 30(4):340-345. PubMed ID: 30086663
[No Abstract] [Full Text] [Related]
17. Use of rituximab in the treatment of mucous membrane pemphigoid: An analytic review.
Farooq MM; Miloslavsky EM; Konikov N; Ahmed AR
Autoimmun Rev; 2022 Aug; 21(8):103119. PubMed ID: 35688385
[TBL] [Abstract][Full Text] [Related]
18. Comparison of immunological parameters in patients with pemphigus vulgaris following rituximab and IVIG therapy.
Feldman RJ; Christen WG; Ahmed AR
Br J Dermatol; 2012 Mar; 166(3):511-7. PubMed ID: 21967407
[TBL] [Abstract][Full Text] [Related]
19. A prospective study comparing patients with early and late relapsing pemphigus treated with rituximab.
Saleh MA
J Am Acad Dermatol; 2018 Jul; 79(1):97-103. PubMed ID: 29408700
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of adjuvant immunoadsorption in pemphigus vulgaris and pemphigus foliaceus (IA-Pem Study): a multicentre randomized controlled trial.
van Beek N; Eming R; Reuss A; Zillikens D; Sárdy M; Günther C; Kiritsi D; Benoit S; Beissert S; Gläser R; Gollnick H; Horváth ON; Pfeiffer C; Röcken M; Schauer F; Schreml S; Steinbrink K; Zink A; Schade-Brittinger C; Hertl M; Schmidt E
Br J Dermatol; 2024 Apr; 190(5):657-667. PubMed ID: 38133541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
